AMR Benchmark homepage

Publication - 10 Jun 2021

New: Biotechs are saving the world from superbugs. Can they also save themselves?

This latest research looks at the small drugmakers driving antibiotic and antifungal R&D and their chances of surviving tough financial conditions to bring new medicines to market. New medicines are urgently needed to stop the AMR crisis.

The AMR Benchmark: independent report on pharma’s response to AMR

The 2020 Antimicrobial Resistance Benchmark compares how pharmaceutical companies are bringing AMR under control. It covers R&D, responsible manufacturing, appropriate access and stewardship.

What leaders say

All endorsements

View our media coverage

Back to top |